NIOSH Seeks Comment on Updated List of Hazardous Drugs in Healthcare

The proposal includes a name change and reorganization of drug lists so that not all antineoplastic drugs, most often associated with cancer treatments, are grouped together. Formerly the “NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings,” the list will be called more simply the “NIOSH List of Hazardous Drugs in Healthcare Settings, 2020.”

Read More »

Network Seeks to Reduce Drug Diversion, Increase Reporting Rate

So far, the network has tracked drug diversion at 90 hospitals, 28 nursing homes, and dozens of other types of healthcare facilities, including ambulatory surgical centers, assisted living centers, clinics, compounding pharmacies, medical laboratories, mental health facilities, pain clinics, rehabilitation homes, retail pharmacies, and schools.

Read More »

Report: Follow Protocols to Help Fight Opioid Addictions

Healthcare providers in U.S. hospitals bear the brunt of the epidemic as they deal with the medical consequences of opioid addiction. From 1999 to 2017, Coverys says, more than 700,000 people died as a result of the opioid epidemic and the number of opioid-related overdoses grew sixfold.

Read More »

Published Review of Independent Double Checks Shouldn’t Dissuade Providers From Using Them Judiciously

ISMP respectfully concludes that little evidence was provided that should cause healthcare providers to abandon the use of judicious and well-placed independent double checks for selected high-alert medications. Instead, ISMP continues to believe that the selective and proper use of manual independent double checks plays an important role in medication safety.

Read More »